All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Luspatercept Approval Shifts Treatment Landscape of Anemia in Lower-Risk MDS

October 24th 2023

Uwe Platzbecker, MD, discusses how to navigate decisions for the first-line treatment of anemia in patients with lower-risk MDS in light of luspatercept’s approval, expands on key data from the COMMANDS trial, and addresses potential concerns from clinicians who are uncertain about when to utilize this agent in the frontline setting in clinical practice.

Amivantamab With or Without Lazertinib Extends PFS in EGFR+ Advanced NSCLC After Progression on Osimertinib

October 23rd 2023

Patients with EGFR-mutated advanced non–small cell lung cancer who experienced disease progression after treatment with osimertinib experienced a progression-free survival benefit with amivantamab plus chemotherapy with or without lazertinib compared with chemotherapy alone.

Dato-DXd Significantly Improves PFS in Select Subsets of Advanced/Metastatic NSCLC

October 23rd 2023

The Trop-2 directed antibody drug conjugate datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer, however those with squamous histology did not experience a benefit.

Relugolix Wins Approval in Canada for Advanced Prostate Cancer

October 23rd 2023

Health Canada has approved relugolix for the treatment of men with advanced prostate cancer.

Frontline VR-CAP Is Effective and Well Tolerated in MZL

October 23rd 2023

Bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride generated robust responses with a tolerable safety profile when delivered as first-line therapy in patients with marginal zone lymphoma.

Frontline Sobuzoxane Plus Etoposide and Rituximab is Safe and Effective in Older DLBCL Population

October 23rd 2023

The combination of sobuzoxane and etoposide plus rituximab prolonged survival and showcased a tolerable safety profile in patients with previously untreated diffuse large B-cell lymphoma aged 80 years and older.

Frontline Amivantamab Plus Lazertinib Bests Osimertinib in Advanced EGFR+ NSCLC

October 23rd 2023

The combination of amivantamab and lazertinib reduced the risk of disease progression or death by 30% compared with osimertinib alone as frontline therapy for patients with advanced non–small cell lung cancer harboring classical EGFR sensitizing mutations.

mRNA-4157 Plus Pembrolizumab Bolsters RFS in Resected Melanoma

October 23rd 2023

The addition of mRNA-4157 to pembrolizumab led to clinically significant improvements in relapse-free survival and distant metastasis–free survival vs pembrolizumab alone in patients with high-risk resected melanoma.

Lenvatinib/Pembrolizumab/Chemo Is Safe With Early Efficacy Signals in mESCC

October 23rd 2023

The combination of lenvatinib, pembrolizumab, and chemotherapy had a manageable safety profile and elicited preliminary antitumor activity in patients with metastatic esophageal squamous cell carcinoma.

Exploratory Analysis Shows Continued Lenvatinib After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

October 23rd 2023

Continued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit vs chemotherapy alone in patients with previously treated advanced endometrial cancer.

Lutetium Lu 177 Vipivotide Tetraxetan Boosts rPFS in Taxane-Naïve mCRPC After Prior AR Inhibitor

October 23rd 2023

Treatment with lutetium Lu 177 vipivotide tetraxetran improved radiographic progression-free survival compared with abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer who were taxane naïve and experienced disease progression on a prior second-generation androgen receptor pathway inhibitor.

Novel Bispecific Antibody EX103 Demonstrates Safety, Elicits Preliminary Antitumor Activity in R/R B-Cell NHL

October 23rd 2023

The novel CD20xCD3 bispecific antibody EX103 displayed a favorable safety profile and produced preliminary antitumor activity in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Dato-DXd Provides PFS Benefit in HR+/HER2– Breast Cancer

October 23rd 2023

Datopotamab deruxtecan elicited a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy for patients with hormone receptor-positive, HER2-low or -negative, metastatic breast cancer.

Lenvatinib/Pembrolizumab Combo Elicits Durable Responses in Advanced ccRCC

October 23rd 2023

Lenvatinib in combination with pembrolizumab led to tumor shrinkage and duration of response benefits compared with sunitinib across subgroups of interest in patients with advanced clear cell renal cell carcinoma.

Cancer Researchers and Student Athletes Are “Here to Win” for Innovation, Discovery, and Hope

October 23rd 2023

Building an innovative cancer research project takes time, creativity, and most importantly, a team of scientists working together on why a new way to treat cancer or keep the cancer from spreading to other parts of the body.

Trastuzumab Deruxtecan Wins EU Approval for HER2-Mutated Advanced NSCLC

October 23rd 2023

The European Commission has approved fam-trastuzumab deruxtecan-nxki for the treatment of patients with advanced non–small cell lung cancer whose tumors harbor an activating HER2 mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.

Subgroup Analysis Shows Dostarlimab/Chemotherapy Elicits PFS Benefit in dMMR/MSI-H, TP53+, and NSMP Endometrial Cancer

October 23rd 2023

Patients with primary advanced or recurrent endometrial cancer whose disease was deficient mismatch repair/microsatellite instability-high, TP53 mutated, or had no specific molecular profile, experienced a survival benefit when treated with dostarlimab-gxly plus chemotherapy vs placebo plus chemotherapy.

Frontline Enfortumab Vedotin Plus Pembrolizumab Elicits OS Improvement in Advanced Urothelial Carcinoma

October 22nd 2023

Frontline treatment with the combination of enfortumab vedotin-ejfv and pembrolizumab led to a statistically significant improvement in overall survival vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Cabozantinib Confers PFS Benefit in Previously Treated Advanced Neuroendocrine Tumors

October 22nd 2023

Patients with advanced neuroendocrine tumors who experienced progression following prior therapy experienced a significant improvement in terms of progression-free survival after treatment with cabozantinib compared with placebo.

Sotorasib Plus Panitumumab Extends PFS in Refractory KRAS G12C+ mCRC

October 22nd 2023

Treatment with combinations using sotorasib at multiple dose levels and panitumumab led to improved progression-free survival vs standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.